, and 1 in 50 experiences drug-induced liver injury 3 . Since genomic variation contributes to other forms of drug-induced liver injury 4, 5 , we aimed to identify biomarkers of IFN-β -induced liver injury using a two-stage genome-wide association study. The rs2205986 variant, previously linked to differential expression of IRF6, surpassed genome-wide significance in the combined two-stage analysis (P = 2.3 × 10 -8 , odds ratio = 8.3, 95% confidence interval = 3.6-19.2). Analysis of an independent cohort of IFN-β -treated MS patients identified via electronic medical records showed that rs2205986 was also associated with increased peak levels of aspartate aminotransferase (P = 7.6 × 10 -5 ) and alkaline phosphatase (P = 4.9 × 10 -4 ). We show that these findings may be applicable to predicting IFN-β -induced liver injury, offering insight into its safer use.
While the therapeutic options for multiple sclerosis (MS) are expanding, interferon-β s (IFN-β s) remain the most widely used disease-modifying therapy. Liver injury secondary to IFN-β has potentially serious sequelae, yet there are no means of predicting this adverse reaction. In the USA, drug-induced liver injury (DILI) is the leading cause of acute liver failure 6 and the most common reason for drug withdrawal from the market 7 . Genome-wide association studies (GWAS) have successfully discovered variants of large effect sizes associated with DILI due to non-biologics using relatively small but rigorously phenotyped cohorts 4, 8 . However, studies identifying variants associated with DILI from biologics, including IFN-β , have not been reported.
Patients who exhibited normal baseline biochemical liver test results before IFN-β exposure were included in this study (see Methods). Cases met a published DILI definition 9 , and controls were exposed to IFN-β for ≥ 2 years, with all biochemical liver test results within the normal range. We recruited 170 patients from Canadian-based MS clinics for stage 1 analyses employing genomewide genotyping. Upon exclusion of samples failing quality control or those of non-European genetic ancestry ( Supplementary Fig. 1 ), 151 samples (38 cases, 113 controls) were subject to whole-genome and human leukocyte antigen (HLA)-allele imputation. Variants reaching P < 1.0 × 10 -6 in stage 1 were tested in stage 2. The clinical and demographic characteristics of stage 1 participants were similar between cases and controls, apart from the controls being more likely to have a relapsing-remitting MS course (P = 0.035; Supplementary Table 1) .
Genome-wide analysis identified three regions associated with IFN-β -induced liver injury, after adjusting for MS disease course (Table 1, Supplementary Tables 2 and 3 , and Supplementary Fig. 2a ). The strongest association was located on chromosome 1q32. 2 Letters Nature GeNetics (rs2205986[G> A], P = 1.9 × 10 -7 , odds ratio (OR) = 8.5, 95% confidence interval (CI) = 3.5-20.4; Table 1 ). This variant also surpassed our screening threshold unadjusted for covariates (P = 3.1 × 10 -7 ) and when adjusted for the first 5 principal components and MS disease course (P = 2.6 × 10 -7
). Analyses of the HLA region did not identify any association with IFN-β -induced liver injury, including HLA variants previously associated with DILI caused by other medications (Supplementary Table 4 ).
The prioritized genomic regions were subsequently tested in stage 2 using a separate cohort of MS subjects from the USA and Sweden (18 cases, 13 controls of European ancestry). Cases were significantly older (P = 0.026), but were similar to controls across other characteristics (Supplementary Table 1 ). Of the variants tested in stage 2, only the 1q32.2 region (rs2205986) was associated with IFN-β -induced liver injury (P = 0.004; Table 1 and Supplementary  Table 3 ). This variant was only observed in cases (Supplementary  Table 2) , and the overall effect (combined stages 1 and 2) surpassed genome-wide significance (P = 2.3 × 10 -8 , OR = 8.3). Next, we evaluated array-genotyped MS patients receiving IFN-β (identified via electronic medical records (EMRs) in the Vanderbilt University Medical Center repository (BioVU)) to assess the influence of the rs2205986 DILI-risk variant on peak biochemical liver test results during IFN-β treatment. Of the 4 liver test results analyzed, rs2205986 was significantly associated with increased aspartate aminotransferase (AST; P = 7.6 × 10 -5 ) and alkaline phosphatase (ALP; P = 4.9 × 10 -4 ) levels (Table 2 and Supplementary Fig. 3 ). On average, each rs2205986 G allele contributed to an increase of 52.3 units l -1 ALP and 29.4 units l -1 AST. Of note, the one BioVU patient homozygous for the rs2205986 G risk-allele presented with elevated peak alanine aminotransferase (ALT), AST and ALP levels (Table 2) , potentially indicating a marked increase in risk associated with this rare genotype. We performed a complementary analysis excluding this sample, which showed a significant association with AST (P = 0.017) but no association for the remaining liver test results. Furthermore, since IFN-β -induced liver injury typically presents with a hepatocellular pattern, we also performed an exploratory case-control analysis of 'mild DILI' (ALT or AST > 2× the upper limit of normal) in the BioVU cohort. These analyses also detected evidence for an association with this phenotype (P = 0.048; OR = 4.3, 95% CI = 1.02-17.8; Table 1 ), indicating that the biomarker may also be useful in identifying milder forms of liver injury.
We also examined the frequency of the top stage 1 regions in a cohort of 1,319 disease-matched population controls that were unscreened for biochemical liver test abnormalities. This confirmed a higher frequency of rs2205986 in cases (minor allele frequency (MAF) = 21.4%) compared with MS population controls (MAF = 9.4%). Although these analyses were no longer genomewide significant (P = 3.0 × 10 -4 ), the use of population controls is best suited to adverse drug reactions with prevalence rates of < 1% 10 . In contrast, 2% of IFN-β -treated MS patients developed DILI, and up to 60% exhibited abnormal biochemical liver test results in a population-based cohort study 3 . Since the BioVU biochemical liver test analyses indicated that rs2205986 is associated with elevated peak liver test results, the depletion in MAF observed in drug-exposed and screened controls may have been caused by the removal of carriers with abnormal biochemical liver test results during the stringent selection process of controls.
Inspection of the 1q32.2 region showed that only rs2205986 surpassed P < 1.0 × 10 -6 , while 30 variants within a 266-kilobase (kb) linkage disequilibrium block displayed P < 5.0 × 10 -5 ( Fig. 1 ). Upon adjusting for rs2205986, no variants were independently associated with DILI (P > 0.05; Supplementary Table 5) . rs2205986 is an intronic variant in synaptotagmin-14 (SYT14); however, this marker is approximately 4.5 kb from the nearest canonical exon and is not predicted to alter SYT14 transcription, splicing, or expression. Notably, in silico annotation using the Genotype-Tissue Expression Project data showed that rs2205986 is an expression quantitative trait locus (eQTL) for the interferon regulatory factor-6 gene (IRF6; P multi-tissue = 5.89 × 10 -17 ) 11 , located 137 kb upstream from rs2205986 ( Fig. 1) .
Interferon regulatory factors (IRFs) are a family of IFN transcription factors that synchronize the type I IFN pathway 12 . Many of the nine known IRFs are associated with promoting liver damage in another model of liver cell death: hepatic ischemia and reperfusion injury 13 . Furthermore, recent gene expression studies have identified IRF6 as an IFN-β drug response biomarker 14 , while IRF3 has been implicated in tolvaptan-induced liver injury 15 . IRF6 promotes apoptosis following brain injury 16 , and previous case reports of MS patients experiencing IFN-β -induced liver injury have shown hepatocyte apoptosis 17 , suggesting that rs2205986-induced alterations in IRF6 expression may promote apoptosis in the presence of IFN-β . The rs2205986-IRF6 eQTL was not significant in liver tissue; however, the effect of this variant on gene expression may be amplified in the presence of IFN-β , or the variant may exert its influence via the blood ( Supplementary Fig. 4 ). Future studies should therefore investigate the influence of this eQTL on IFN-β -induced hepatic expression.
The HLA region has been shown to confer risk to DILI caused by certain drugs 4, 5 ; however, no HLA alleles or variants outside the HLA region that have previously been associated with DILI (for example, glutathione S-transferase and ATP-binding cassette transporter genes) 18, 19 reached the screening threshold. As previous pharmacogenomic studies of DILI investigated non-biologics, these results might be expected given the differences in the metabolism of biologics compared with small-molecule drugs 19 , and the limited evidence surrounding IFN-β metabolism 20 . We also incorporated rs2205986 into a predictive model for DILI. Including rs2205986 significantly improved the prediction of . Pharmacogenomic testing for HLA-B*1502 before carbamazepine use is recommended by the Food and Drug Administration for certain ancestries, highlighting the importance of the current findings. Future studies could consider incorporating additional variables, such as the absolute baseline liver biochemistry values, into predictive models to further improve prediction.
To our knowledge, few others have investigated the genetic architecture of adverse drug reactions from an MS therapy. These analyses were restricted to European genetic ancestry patients to minimize population stratification. However, since MS is known to be most prevalent in those with northern European ancestry 22 , these results are expected to be applicable to the majority of people with MS. Furthermore, objectively defining DILI 9 and applying stringent inclusion criteria for the controls in this study enhanced the statistical power 10 . Nonetheless, sample size remains a limitation, and as a consequence, we were only able to identify one pharmacogenomic predictor of IFN-β -induced liver injury. Future studies of larger cohorts might improve the ability to detect additional variants of smaller effect.
In conclusion, we have identified an association between an IRF-related eQTL and IFN-β -induced liver injury. These findings have important implications for the development of strategies to reduce the occurrence of IFN-β -induced liver injury in MS patients. Pharmacogenomic testing for this variant before IFN-β therapy, rather than only monitoring liver enzymes during treatment, may prevent DILI in at-risk patients. Prevention of DILI in rs2205986 carriers could then be achieved by either considering alternative therapies or increased monitoring of liver injury. In addition, our findings set the stage for functional assessments of IRF6, rs2205986, and IFN-β treatment to provide a mechanistic understanding of this pharmacogenomic association that can be specifically targeted to prevent DILI. uRLs 1000 Genomes database, http://www.1000genomes.org; PLINK, https://www.cog-genomics.org/plink2; R for statistical computing 3.2.3, http://www.r-project.org/; Wellcome Trust Case Control Consortium, www.wtccc.org.uk; GTEx Portal, www.gtexportal.org
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41588-018-0168-y. . Three genes (MIR4260, TRAF3IP3, and C1orf74) were omitted from the figure due to space requirements. 
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Methods Study participants. Subjects were eligible for inclusion in our study if they had either relapsing-remitting or secondary-progressive definite MS (based on Poser or McDonald criteria) 23, 24 , documented exposure to an IFN-β product (subcutaneous IFN-β -1b (250 μ g every other day), subcutaneous IFN-β -1a (22 μ g or 44 μ g 3× weekly) or intramuscular IFN-β -1a (30 μ g weekly)) and had a normal baseline liver enzyme test. At least one ALT test result was required for baseline assessment. Cases met at least one of the following criteria 9 : (1) ALT or AST ≥ 5× the upper limit of normal; (2) ALT ≥ 3× the upper limit of normal, with simultaneous elevation of bilirubin > 2× the upper limit of normal; or (3) ALP > 2× the upper limit of normal. Controls were exposed to IFN-β for at least two years with all biochemical liver test results within normal limits based on the normal ranges for the site-specific laboratory.
As the first 15 months of IFN-β exposure are considered the greatest risk period for developing de novo ALT elevations 2 , and all cases developed DILI within 700 days of beginning IFN-β 3 , 2 years of IFN-β exposure was required to determine whether a participant was truly a control. As expected due to the study design, stage 1 controls were exposed to IFN-β for a significantly longer duration (median: 82 months, interquartile range: 51-110.5 months) than cases (median: 4 months; interquartile range: 2.5-27.5 months; P = 6.0 × 10 -15 ). Moreover, all biochemical liver test results for controls had to be within the normal reporting range, which further limited the size of our control sample given that 30-60% of MS patients exposed to IFN-β will experience de novo liver enzyme elevations 1, 2 . Although limiting our sample size for IFN-β -exposed controls, these stringent inclusion criteria increased the confidence in the clinical phenotype, enhancing our power to detect genetic variants of clinical relevance.
Participants included in stage 2 were recruited from three sites: a USA-based clinic (Partners HealthCare MS Clinic, Boston, MA) and two national adverse drug reaction surveillance networks located in the USA (the Drug-Induced Liver Injury Network 25, 26 ) and Sweden (SWEDEGENE; http://www.swedegene. se/). Inclusion criteria for patients recruited from the Drug-Induced Liver Injury Network matched those from other centers except that two consecutive elevations of the same magnitude described above for ALT, AST, or ALP were required 26 . The relevant research ethics board of each participating institution approved the study, and all participants provided written informed consent. This study complies with all relevant ethical regulations.
Clinical characterization. Each patient's medical record was reviewed before genotyping to capture demographic and clinical information and a comprehensive characterization of the adverse drug reaction, including drug exposure information and biochemical liver test results. The following information was collected from medical charts for all patients: demographics (sex, date of birth, and self-reported ancestry), body mass index, MS disease characteristics (that is, the MS disease course at IFN-β initiation (relapsing-remitting or secondary-progressive)), medications (IFN-β product (dose, route of administration, and start and stop dates) and concurrent medication usage (generic name, route of administration, dose, frequency, and start and stop dates, where possible)), and biochemical liver test results (date of test, test result (and value, if abnormal), and reporting laboratory upper limit of normal, if abnormal).
Genotyping, quality control, and imputation. Genome-wide genotyping was performed for the stage 1 participants (n = 170) using the Illumina MEGA array (1,705,969 genetic variants) followed by stringent sample and variant quality control methods. The stage 2 cohort was genotyped either in the same manner (n = 10) or as part of a genome-wide analysis of MS disease risk, as described previously 27 (n = 24). For the participants genotyped as part of the MS disease risk study, access to imputed genotype data allowed for the extraction of the variants of interest where necessary.
The following combination of thresholds for quality control metrics were implemented using either QCTOOL (version 2; http://www.well.ox.ac.uk/~gav/ qctool_v2/), GTOOL (version 0.7.5; http://www.well.ox.ac.uk/~cfreeman/software/ gwas/gtool.html) or PLINK (version 1.90) 28 . Genetic variants with a low call rate (< 95%), a MAF of < 1% in both cases and controls, and those deviating from Hardy-Weinberg equilibrium genotype distributions (P < 1.0 × 10 -6 in controls) were excluded. No samples were related (using an identity-by-descent estimation metric ≤ 0.15). Three patient samples in the stage 1 cohort were excluded due to a low sample call rate. Non-autosomal markers were excluded from the analyses.
Genotype Harmonizer (1.4.15) 29 was used to ensure that variants were on the correct strand to facilitate imputation. Phasing was performed with SHAPEIT (version 2), followed by whole-genome imputation using IMPUTE2 (version 2.3.2) 29 and the Phase 3 1000 Genomes Project reference panel 30 . Markers with imputation information metrics ≥ 0.5 were included in the subsequent analyses. Imputation of classical HLA alleles and HLA region variants was performed with SNP2HLA (version 1.0.2) 31 using the stage 1 cohort genotype data and the Type 1 Diabetes Genetics Consortium reference panel. HLA alleles and related variants with imputation scores of R 2 ≤ 0.5 and a call rate < 0.85 were excluded from the subsequent analyses.
Genotyping calls of genome-wide significant variants (rs2205986) were validated in the stage 1 cohort patients using TaqMan genotyping assays (TaqMan Genotyper Software; Thermo Fisher Scientific) and exhibited 100% concordance with the array genotype (Supplementary Fig. 6 ).
GWAS stage 1 and stage 2 statistical analyses. Categorical variables (sex, MS
disease course (relapsing-remitting or secondary-progressive), IFN-β product, liver injury pattern (hepatocellular, cholestatic, or mixed), and concomitant hepatotoxic medication use) were summarized by frequency (%), with age at IFN-β initiation and body mass index (continuous variables) summarized using the median (interquartile range) or mean (s.d.). Clinical and demographic factors were compared between cases and controls using the appropriate parametric (Pearson's chi-squared test or Student's t-test) or non-parametric tests (Fisher's exact test or Mann-Whitney U-test), and associations with P < 0.05 were considered significant (all P values were two-tailed).
Genetic ancestry was confirmed using principal components analysis (EIGENSTRAT method) 32 , which was subsequently compared with self-reported ethnicity, with patients excluded based on non-European ancestry. To minimize the potential confounding effects of population stratification, a total of 16 (stage 1) and 3 (stage 2) samples were removed from the analyses owing to non-European ancestry (Supplementary Fig. 1 ). The first 10 principal components were re-calculated within the individuals who were of European genetic ancestry in stage 1 (n = 151), with no significant difference between cases and controls (Student's t-test, P > 0.1). Additionally, a genomic inflation factor of 1.06 indicates that the stage 1 participants (n = 151) used for genome-wide discovery were not notably influenced by population stratification (Supplementary Fig. 2b) .
The association for each genomic marker passing quality control assessment with case or control status was tested using logistic regression in an additive model (adjusted for relevant clinical and demographic factors), with findings expressed as ORs with 95% CIs. A screening threshold (P < 1.0 × 10 -6 ) was applied to the stage 1 cohort to prioritize variants for subsequent stage 2 analyses, where P < 0.05 was considered significant. Associations reaching the standard genome-wide significance threshold (P < 5.0 × 10 -8
) across the combined cohort (that is, stages 1 and 2) were considered to be statistically significant. For the HLA region, an HLA-wide significance threshold of P < 2.3 × 10 -4 was set to account for Bonferroni correction for the 219 HLA alleles present in the cohort. P < 0.05 was considered significant for the replication of previously reported associations with HLA alleles and DILI.
Genome-wide association analyses were performed with SNPTEST (version 2; https://mathgen.stats.ox.ac.uk/genetics_software/snptest/snptest.html), and other statistical analyses were performed using Golden Helix SVS (version 8.4; Bozeman, MT, USA), IBM SPSS (version 22.0; Mississauga, Canada), or R for Statistical Computing (version 3.2.3). Plots (Manhattan plot, regional association plot, and the receiver operating characteristic (ROC) curve) were generated using LocusZoom 33 , R for Statistical Computing, or Golden Helix SVS.
BioVU EMR analyses. BioVU population.
A total of 279 MS patient samples previously genotyped at Vanderbilt University Medical Center (VUMC) were accessed. The samples were part of BioVU-a de-identified collection of DNA samples extracted from discarded blood and linked to de-identified EMRs 34 . All samples were identified as being from an individual with MS by previously published algorithms 35 . The EMRs were evaluated manually to identify dates of IFN-β treatment. Biochemical liver test results (ALT, AST, ALP, and total bilirubin) were extracted from structured fields of the EMRs during IFN-β treatment. A total of 87 unique MS patients were exposed to IFN-β , had a sample and available biochemical liver test results during IFN-β treatment, and were used in subsequent analyses. The highest value for each biochemical liver test result was identified independent of the other biochemical liver test results. For patients with more than one IFN-β treatment period, only the treatment period with the highest overall value was analyzed. Additionally, IFN-β -induced liver injury often presents with an hepatocellular pattern 3 . An exploratory analysis of 'mild DILI' was performed where cases had either ALT or AST levels > 2× the upper limit of normal.
BioVU genotyping, quality control, and statistical analyses. Samples were genotyped on the Illumina MEGA EX array at VUMC. Quality control was performed by BioVU as previously described 36 , and array genotype data for rs2205986 were extracted. Relationship status was evaluated using PLINK 28 and revealed no related individuals (identity by descent: ≤ 0.15). Principal components were determined by multidimensional scaling in PLINK 28 . One patient sample was excluded from the ALP analyses due to being an outlier (> 3 s.d. above the mean). BioVU association analyses were performed using PLINK 28 . The rs2205986 genotype was analyzed using an additive genetic model by linear regression for association with the highest values for each of the four biochemical liver test results during IFN-β treatment, while logistic regression was employed in the case-control association analyses. BioVU linear regression analyses were adjusted for age at biochemical liver testing, sex, and the first two principal components.
Disease-matched population control analyses. Genotype data (Illumina Human670-QuadCustom v1) for disease-matched population controls were obtained from the MS Wellcome Trust Case Control Consortium 2 cohort Letters Nature GeNetics (EGAD00000000120) 37 after approval from the relevant data access committees. We included MS patients recruited in North America and determined to be of northern European genetic ancestry ( Supplementary Fig. 7 ), leaving 1,319 patients for these analyses. Quality control, strand alignment, and whole-genome imputation were performed as described above.
Predictive test analyses. Genomic markers of statistical significance were evaluated for specificity, sensitivity, negative predictive value, positive predictive value, and the number needed to screen within the combined patient cohort. Negative predictive value, positive predictive value, and the number needed to screen were calculated using sensitivity, specificity, and the population incidence of IFN-β -induced liver injury (2%) 3 . Post-test probabilities to estimate the proportion of patients testing positive for the variant who will develop DILI were assessed using likelihood ratios and pre-and post-test odds (http://www.cebm.net/ likelihood-ratios/). ROC curves, the corresponding area under the curve estimates, and 95% CIs were generated for two predictive models of IFN-β -induced liver injury. The clinical model included age, IFN-β product, and sex (selected a priori based on previous DILI literature reporting significantly associated factors) 38 , and a separate model incorporated these same variables in addition to any significantly associated genomic variants. The ROC curves of these two prediction models were compared using DeLong's test 39, 40 .
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Sample size
Our study was designed and powered (>85%) to identify associations with large effect sizes (per-allele OR ≥ 8.0) at a minor allele frequency of ≥ 0.10. Sample size estimation was performed using Quanto (v.1.2.4)
Data exclusions Samples were excluded from analyses if they failed quality control or if they were of non-European genetic ancestry.
Replication
The experimental findings were reliably reproduced in two independent cohorts of interferon-beta treated multiple sclerosis patients.
Randomization Samples were not randomly allocated into experimental groups, however all analyses were adjusted for any relevant covariates. More specifically the following adjustments were made: Genome-wide association analyses for the Stage 1 cohort (Table 1) was adjusted for MS disease course because controls were more likely to have a relapsing-remitting MS course than cases. The genome-wide association analyses in Stage 1 were also adjusted for the first five principal components and MS disease course. Genomic association analyses for the Stage 2 cohort were adjusted for age given that cases were significantly older than controls. We also adjusted the genomic association analyses of any additional variants that were within a 266-kb linkage disequilibrium block of the top variant (rs2205986) and were P<5.0x10-5 for the presence of rs2205986. BioVU linear regression analyses were adjusted for age at biochemical liver testing, sex, and the first two principal components.
Blinding
Not applicable. Investigators were not blinded to group allocation.
Reporting for specific materials, systems and methods The characteristics of the sample population utilized in the Stage 1 and 2 aspects of this study were typical of a interferon-beta
